Kategorier: pharma specials

2 Juni 2025 09:00

Melatonin Unimedic Pharma 1 mg/ml drink for children with ADHD and insomnia now available in the Belgian market

Unimedic Pharma AB, in partnership with its distributor TwinPharma BV, has launched Melatonin Unimedic Pharma 1 mg/ml drink in Belgium.
Johan Frödin, CEO of Unimedic Pharma says: "This marks a significant step for children with ADHD and insomnia. Our commitment to innovation and patient care drives us to develop solutions that address unmet medical needs, and we are very proud to offer this tre

20 December 2023 08:51

Unimedic Pharma AB out-license Melatonin oral solution in Belgium to TwinPharma BV

Unimedic Pharma AB has signed a distribution agreement with TwinPharma BV for the launch of Melatonin 1 mg/ml oral solution in Belgium.
Unimedic Pharma and TwinPharma entered into a supply and distribution agreement in 2017 and the addition of Melatonin 1mg/ml is the third product in the collaboration.
In this partnership, TwinPharma is appointed exclusive distributor of Melatonin Unimedi

20 September 2016 08:00

Unimedic announces new distribution agreement with Basilea for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries

Stockholm, September, 20th 2016 – Unimedic Pharma AB announced today that Unimedic has entered into a licence and distribution agreement with Basilea Pharmaceutica Ltd. (SIX: BSLN) for Basilea’s antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in the Nordic countries, including Sweden, Denmark, Norway and Finland.

30 Juni 2016 10:30

Unimedic Pharma® Announces Extension of Licensing Agreement with Martindale Pharma to include Emergency Care Product Portfolio

Unimedic Pharma, the Sweden based specialty pharma company today announced a new agreement with its strategic partner Martindale Pharma for its Emergency/Intensive Care sterile ampoule products in Sweden, Denmark, Norway and Finland. The products will be available in the end of 2017 or beginning of 2018.

7 Juni 2016 13:21

Unimedic har tagit över ansvaret att producera och tillhandahålla Neostigmin® från den 1 juni. Syftet bakom övertagandet är att säkerställa att produkten är tillgänglig för de patienter som har behov.

​Unimedic har kommit överens med Stada Nordic (PharmaCoDane) att ta över ansvaret för Neostigmin® från och med den 1 juni 2016. Neostigmin är en viktig produkt för en mindre grupp patienter där det finns behov att reversera icke depolariserande muskelrelaxantia (återfå normal muskelfunktion). Den fulla indikationen är tarm- och blåsatoni. Myasthenia gravis.

21 Mars 2013 16:12

Unimedic AB förvärvar produkten Metadon

Unimedic AB förvärvar produkten Metadon Pharmadone och stärker därmed sin position som ledande aktör inom flytande läkemedel och Pharma Specials.